$KRRO

FORMELA JEAN FRANCOIS sold $1.5M of KRRO (indirect holdings)

FORMELA JEAN FRANCOIS sold 110,023 indirectly-held shares of Korro Bio, Inc. (KRRO) at an average of $14.02 ($13.96–$14.03, $1.54M total) across 4 trades over 2026-07-02 to 2026-07-06 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · FORMELA JEAN FRANCOIS
Published Jul 7, 2026, 10:04 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 7, 2026, 10:07 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KRRO
Neutral
medium confidence
Mentioned
$KRRO
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KRRONeutralLow
01

Why it matters

The newest concrete fact is the director’s open-market sale totaling ~$1.54M at ~$13.96–$14.03 per share, executed across four trades under a 10b5-1 plan.

02

Market read

Primarily a sentiment/positioning datapoint; no new guidance, trial, deal, or regulatory development is disclosed.

03

What to watch

Traders may still watch for follow-on insider activity (additional Form 4s) or whether other insiders/large holders are selling/buying around the same window.

Relevance 5/10Novelty 3/10Timing: Filed after-hours on 2026-07-07; reflects sales executed 2026-07-02 to 2026-07-06.

Background

The article is an SEC Form 4 insider transaction disclosure for Korro Bio, Inc. (KRRO).

Company-level read

Ticker impact

$KRRONeutralMedium confidence
Context

Korro Bio director Formela Jean Francois sold $1.54M of KRRO via an open-market sale under a pre-arranged 10b5-1 plan (110,023 shares).

Expected impact

Likely limited near-term impact; any effect is more sentiment/flow-related than fundamental.

Evidence & confidence

The filing is a routine Form 4 open-market sale with a stated 10b5-1 plan, and the article provides no new operational/regulatory/financial catalyst.

Market effects

No sector read-through; this is company-specific insider transaction data.

None indicated.

None indicated.

Counterpoint

Because the sale is under a pre-arranged 10b5-1 plan, the transaction may be mechanically scheduled and not a bearish signal.

Key entities

  • Korro Bio, Inc.

    US-listed company whose director insider sale is disclosed on Form 4.

  • Formela Jean Francois

    Director who sold 110,023 shares indirectly under a pre-arranged 10b5-1 plan.

Related articles

$KRROMed

Korro Bio, Inc. (KRRO): Results of Operations and Financial Condition

Korro Bio, Inc. (KRRO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 4 krro-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 Korro Reports Second Quarter 2026 Financial Results and Provides Corporate Update — KRRO-121, a potential first-in-class transformational treatment for hyperammonemia, remains on track to commence first-in-human clinical tria